IL305827A - Bispecific antibodies targeting CD47 and PD-L1 and methods of using them - Google Patents

Bispecific antibodies targeting CD47 and PD-L1 and methods of using them

Info

Publication number
IL305827A
IL305827A IL305827A IL30582723A IL305827A IL 305827 A IL305827 A IL 305827A IL 305827 A IL305827 A IL 305827A IL 30582723 A IL30582723 A IL 30582723A IL 305827 A IL305827 A IL 305827A
Authority
IL
Israel
Prior art keywords
methods
bispecific antibodies
antibodies targeting
targeting
bispecific
Prior art date
Application number
IL305827A
Other languages
English (en)
Hebrew (he)
Inventor
Xavier Chauchet
Krzysztof Masternak
Limin Shang
Giovanni Magistrelli
Nicolas Fischer
Original Assignee
Novimmune Sa
Xavier Chauchet
Krzysztof Masternak
Limin Shang
Giovanni Magistrelli
Nicolas Fischer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa, Xavier Chauchet, Krzysztof Masternak, Limin Shang, Giovanni Magistrelli, Nicolas Fischer filed Critical Novimmune Sa
Publication of IL305827A publication Critical patent/IL305827A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL305827A 2021-03-22 2022-03-22 Bispecific antibodies targeting CD47 and PD-L1 and methods of using them IL305827A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163164329P 2021-03-22 2021-03-22
US202263317899P 2022-03-08 2022-03-08
PCT/EP2022/057555 WO2022200389A1 (en) 2021-03-22 2022-03-22 Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof

Publications (1)

Publication Number Publication Date
IL305827A true IL305827A (en) 2023-11-01

Family

ID=81384718

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305827A IL305827A (en) 2021-03-22 2022-03-22 Bispecific antibodies targeting CD47 and PD-L1 and methods of using them

Country Status (7)

Country Link
US (1) US12448444B2 (https=)
EP (1) EP4314065A1 (https=)
JP (1) JP2024511137A (https=)
AU (1) AU2022245196A1 (https=)
CA (1) CA3212056A1 (https=)
IL (1) IL305827A (https=)
WO (1) WO2022200389A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12448444B2 (en) 2021-03-22 2025-10-21 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
IL305828A (en) * 2021-03-22 2023-11-01 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
EP4493592A1 (en) 2022-03-14 2025-01-22 LamKap Bio gamma AG Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
US20240254223A1 (en) * 2022-09-02 2024-08-01 Novimmune Sa Reciprocally masked antibody-cytokine fusion proteins and methods of use thereof
US20240254234A1 (en) 2022-10-21 2024-08-01 Novimmune Sa PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
WO2025133389A1 (en) * 2023-12-22 2025-06-26 Numab Therapeutics AG Antibody binding domains having specificity for lilrb2
EP4574844A1 (en) * 2023-12-22 2025-06-25 Numab Therapeutics AG Multispecific antibodies having specificity for cd47 and pdl1

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
CN102459591B (zh) 2009-05-20 2015-05-13 诺维莫尼公司 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法
WO2011084255A2 (en) 2009-12-17 2011-07-14 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
PT2768857T (pt) 2011-10-19 2020-01-27 Novimmune Sa Métodos para purificar anticorpos
DK3725807T3 (da) 2012-12-03 2026-01-12 Novimmune Sa Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
US11260117B2 (en) 2017-05-26 2022-03-01 Novimmune Sa Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
AU2018303254B2 (en) * 2017-07-21 2025-05-29 Novimmune Sa Generating multispecific antibody mixtures and methods of uses thereof
EP3722322A4 (en) * 2017-12-04 2021-09-15 Beijing Hanmi Pharmaceutical Co., Ltd. ANTI-PD-L1 / ANTI-CD47 BISPECIFIC ANTIBODY HAVING A NATURAL ANTIBODY STRUCTURE AND IN THE FORM OF A HETERODIMER, AND ASSOCIATED PREPARATION
EP3802599B1 (en) 2018-06-03 2023-12-20 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
US12448444B2 (en) 2021-03-22 2025-10-21 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
IL305828A (en) 2021-03-22 2023-11-01 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
KR20240165995A (ko) 2022-03-24 2024-11-25 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암의 치료를 위한 병용요법
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法

Also Published As

Publication number Publication date
EP4314065A1 (en) 2024-02-07
JP2024511137A (ja) 2024-03-12
WO2022200389A1 (en) 2022-09-29
US20220315655A1 (en) 2022-10-06
US12448444B2 (en) 2025-10-21
AU2022245196A1 (en) 2023-09-21
CA3212056A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
IL305827A (en) Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
IL305828A (en) Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
GB202019709D0 (en) Anti-Coronavirus antibodies and methods of use
SG11202011461TA (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use
EP4031177A4 (en) ANTI-TNFR2 ANTIBODIES AND METHOD OF USE
IL280225A (en) New antibodies against CD47 and methods of using them
ES3064823T3 (en) Anti-ly6g6d antibodies and methods of use
IL287282A (en) Anti-mertk antibodies and methods of using them
SG11202108403UA (en) Anti-clec2d antibodies and methods of use thereof
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
SMT202500106T1 (it) Anticorpi anti-par-2 e loro metodi d'uso
IL277211A (en) Dual specific antibodies for human PD-L1 and PD-L2 and methods of their use
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
IL310780A (en) Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof
IL298668B1 (en) Anti-CD200R1 antibodies and methods of using them
IL288886A (en) Antibodies and methods of use
IL308260A (en) Antibodies against Tigit and methods of using them
IL310861A (en) Bispecific antibodies against FLT3 and CD3 and methods of use
HK40110029A (en) Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
IL325840A (en) Bispecific PD-L1XCD28 antibodies and methods of using them
IL325837A (en) Bispecific PD-L1X4-1BB antibodies and methods of using them
IL310551A (en) Monoclonal antibodies specific for OSMR and methods of using them
CA3297983A1 (en) Bispecific pd-l1xcd28 antibodies and methods of use thereof
CA3297963A1 (en) Bispecific pd-l1x4-1bb antibodies and methods of use thereof
IL325608A (en) Bispecific antibody targeting PD L1 and IL 1 and its uses